Scott Randal W. 4
4 · BridgeBio Pharma, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Scott Randal W.
Director
Transactions
- Sale
Common Stock
2025-11-17$66.25/sh−3,801$251,809→ 17,788 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-17−10,000→ 41,501 totalExercise: $16.75Exp: 2033-06-21→ Common Stock (10,000 underlying) - Sale
Common Stock
2025-11-17$66.89/sh−6,199$414,656→ 11,589 total - Exercise/Conversion
Common Stock
2025-11-17$16.75/sh+10,000$167,500→ 21,589 total
Holdings
- 4,000(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.
- [F2]Represents the weighted average sale price of the shares sold from $65.64 to $66.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold from $66.65 to $67.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F4]One-third of the shares underlying the option vested on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the Reporting Person's continued service on the board of directors of the Issuer.